MCID: GST071
MIFTS: 46

Gastrointestinal Carcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Gastrointestinal Carcinoma

MalaCards integrated aliases for Gastrointestinal Carcinoma:

Name: Gastrointestinal Carcinoma 12 54 6 15 70
Gastrointestinal Neoplasms 70

Classifications:



External Ids:

Disease Ontology 12 DOID:0050922
UMLS 70 C0017185 C0151544

Summaries for Gastrointestinal Carcinoma

Disease Ontology : 12 A gastrointestinal system cancer that has material basis in epithelial cells.

MalaCards based summary : Gastrointestinal Carcinoma, also known as gastrointestinal neoplasms, is related to mucositis and adenoma, and has symptoms including signs and symptoms, digestive An important gene associated with Gastrointestinal Carcinoma is KRT20 (Keratin 20), and among its related pathways/superpathways are Cell surface interactions at the vascular wall and Interleukin-4 and 13 signaling. The drugs Celecoxib and Tramadol have been mentioned in the context of this disorder. Affiliated tissues include liver, pancreas and lymph node, and related phenotypes are digestive/alimentary and neoplasm

Related Diseases for Gastrointestinal Carcinoma

Diseases related to Gastrointestinal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 308)
# Related Disease Score Top Affiliating Genes
1 mucositis 30.2 TYMS MMP2 DPYD
2 adenoma 30.0 TP53 MUC1 KRT20 CDX2
3 gastric ulcer 29.9 TP53 IL6 GAST
4 rectum cancer 29.9 TYMS KRT20 DPYD CEACAM7 CEACAM5
5 neutropenia 29.8 TYMS TP53 IL6 DPYD
6 gastric adenocarcinoma 29.7 TP53 KRT20 GAST CEACAM5 CDX2
7 microinvasive gastric cancer 29.7 TP53 GAST CEACAM5 CDX2
8 villous adenoma 29.6 TP53 MUC1 KRT20 CEACAM5 CDX2
9 pseudomyxoma peritonei 29.6 TP53 MUC1 KRT20 CEACAM5 CDX2
10 transitional cell carcinoma 29.5 TP53 KRT20 KRT19 CD44
11 colon adenocarcinoma 29.5 TYMS TP53 KRT20 EPCAM CEACAM7 CEACAM5
12 intrahepatic cholangiocarcinoma 29.4 TP53 MUC1 KRT20 KRT19 EPCAM CDX2
13 adenocarcinoma 29.4 TP53 MUC1 MMP2 KRT20 EPCAM CEACAM6
14 squamous cell carcinoma 29.1 TP53 MUC1 MMP2 KRT19 EPCAM CEACAM5
15 small cell carcinoma 29.1 TP53 PTPRC MUC1 KRT20 KRT19 GAST
16 basal cell carcinoma 28.8 TP53 MMP2 KRT20 KRT19 IL6 CEACAM5
17 esophageal cancer 28.8 TYMS TP53 MUC1 MMP2 KRT19 IL6
18 cholangiocarcinoma 28.0 TP53 MUC1 KRT20 KRT19 IL6 CEACAM6
19 gastric cancer 27.5 TYMS TP53 MUC1 MMP2 KRT20 KRT19
20 pancreatic cancer 27.5 TYMS TP53 MUC1 MMP2 KRT20 KRT19
21 lung cancer 27.3 TYMS TP53 PTPRC MUC1 MMP2 KRT19
22 larynx sarcoma 10.4 EPCAM CEACAM5
23 mucinous intrahepatic cholangiocarcinoma 10.4 MUC1 CDX2
24 rectum signet ring adenocarcinoma 10.4 EPCAM CEACAM5
25 ureter adenocarcinoma 10.4 CEACAM5 CDX2
26 laryngeal mucoepidermoid carcinoma 10.4 CEACAM5 CDX2
27 mucinous adenofibroma 10.4 CEACAM5 CDX2
28 anal paget's disease 10.4 CEACAM5 CDX2
29 cystitis cystica 10.4 KRT20 CDX2
30 descending colon cancer 10.4 CEACAM5 CDX2
31 vulvar eccrine porocarcinoma 10.4 MUC1 CEACAM5
32 urethral villous adenoma 10.4 KRT20 CEACAM5
33 nodular hidradenoma 10.4 MUC1 CEACAM5
34 jejunal cancer 10.4 KRT20 CDX2
35 bile duct cystadenocarcinoma 10.4 MUC1 CEACAM5
36 pancreatic serous cystadenocarcinoma 10.4 KRT20 CEACAM5
37 appendiceal neoplasm 10.4 CEACAM5 CDX2
38 rectum neuroendocrine neoplasm 10.4 GAST CDX2
39 intrahepatic gall duct cancer 10.4 KRT19 EPCAM
40 appendix adenocarcinoma 10.4 KRT20 CDX2
41 mucinous bronchioloalveolar adenocarcinoma 10.4 KRT20 CDX2
42 jejunal adenocarcinoma 10.4 KRT20 CDX2
43 pancreatic signet ring cell adenocarcinoma 10.4 TP53 MUC1
44 rectosigmoid junction neoplasm 10.4 KRT20 CEACAM5
45 transverse colon cancer 10.4 KRT20 CEACAM5
46 biliary papillomatosis 10.4 MUC1 CEACAM5
47 bile duct mucoepidermoid carcinoma 10.3 MUC1 CEACAM5
48 ovarian seromucinous carcinoma 10.3 TP53 CDX2
49 bile duct mucinous adenocarcinoma 10.3 TP53 MUC1
50 mucoepidermoid esophageal carcinoma 10.3 TP53 CEACAM5

Graphical network of the top 20 diseases related to Gastrointestinal Carcinoma:



Diseases related to Gastrointestinal Carcinoma

Symptoms & Phenotypes for Gastrointestinal Carcinoma

UMLS symptoms related to Gastrointestinal Carcinoma:


signs and symptoms, digestive

MGI Mouse Phenotypes related to Gastrointestinal Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.65 CD44 CDX1 CDX2 DPYD EPCAM GAST
2 neoplasm MP:0002006 9.23 CD44 CDX2 GAST IL6 KRT19 MMP2

Drugs & Therapeutics for Gastrointestinal Carcinoma

Drugs for Gastrointestinal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 311)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
2
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
3
parecoxib Approved Phase 4 198470-84-7
4
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
5
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
6
Zinc Approved, Investigational Phase 4 7440-66-6 32051
7
Insulin glargine Approved Phase 4 160337-95-1
8
Sirolimus Approved, Investigational Phase 4 53123-88-9 6436030 5284616
9
Enoxaparin Approved Phase 4 9005-49-6 772
10 Cyclooxygenase 2 Inhibitors Phase 4
11 Respiratory System Agents Phase 4
12 Pharmaceutical Solutions Phase 4
13 Adrenergic alpha-Agonists Phase 4
14 Vasoconstrictor Agents Phase 4
15 Adrenergic beta-Agonists Phase 4
16 Anti-Asthmatic Agents Phase 4
17 Sympathomimetics Phase 4
18 Mydriatics Phase 4
19 Adrenergic Agents Phase 4
20 Anesthetics, Local Phase 4
21 Adrenergic Agonists Phase 4
22 Bronchodilator Agents Phase 4
23 insulin Phase 4
24 Insulin, Globin Zinc Phase 4
25 glutamine Phase 4
26 Neuromuscular Nondepolarizing Agents Phase 4
27 Neuromuscular Blocking Agents Phase 4
28 Hypoglycemic Agents Phase 4
29 Anticoagulants Phase 4
30 Fibrinolytic Agents Phase 4
31
Formaldehyde Approved, Vet_approved Phase 3 50-00-0 712
32
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
33
Palonosetron Approved, Investigational Phase 3 119904-90-4, 135729-56-5 148211
34
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
35
Durvalumab Approved, Investigational Phase 3 1428935-60-7
36
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 5310940 9887054 43805 6857599
37
Gemcitabine Approved Phase 3 95058-81-4 60750
38
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
39
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
40
Lapatinib Approved, Investigational Phase 3 231277-92-2, 388082-78-8 208908 9941095
41
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
42
Sorafenib Approved, Investigational Phase 3 284461-73-0 216239 406563
43
Dopamine Approved Phase 3 62-31-7, 51-61-6 681
44
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
45
Melatonin Approved, Nutraceutical, Vet_approved Phase 3 73-31-4 896
46 Pancreatic Polypeptide Investigational Phase 2, Phase 3 59763-91-6
47 Reishi Phase 3
48 Protective Agents Phase 3
49 Antioxidants Phase 3
50 Serotonin 5-HT3 Receptor Antagonists Phase 3

Interventional clinical trials:

(show top 50) (show all 449)
# Name Status NCT ID Phase Drugs
1 Clinical Trial of Cinobufacini Injection Combined With Oxaliplatin Regimen on Gastrointestine Carcinoma Unknown status NCT02860429 Phase 4 Cinobufacini injection;chemotherapy
2 Study of the Relationship Between the Rate of Residual Platinum in the Blood and the Incidence of Persistent Neurotoxicity in Patients Treated for Gastrointestinal Cancer With Oxaliplatin Unknown status NCT00274885 Phase 4 oxaliplatin
3 Effect of COX-2 Selective Inhibitors on Postoperative Insulin Resistance, Tramadol PCA and Early Postoperative Enteral Nutrition in Patients After Gastrointestinal Laparoscopic Surgery Unknown status NCT01930318 Phase 4 parecoxib
4 Comparing With Traditional Nitrogen Calorie Parenteral Nutrition Support, the Impact of Low Calorie and Low Nitrogen Intake on the Clinical Outcome of Gastrointestinal Postoperative Patients, Multicentre Post-Marketing Clinical Study Completed NCT00247338 Phase 4 low calorie, low nitrogen parenteral nutrition for patient with NRS score 3
5 A Single-arm, Open-label, Multi-center, Phase Iv, Efficacy And Safety Study Of Sunitinib Malate In The Treatment Of Chinese Patients With Gastrointestinal Stromal Tumor After Disease Progression On Or Intolerance To Imatinib Mesylate Completed NCT00793871 Phase 4 Sunitinib Malate (SU011248)
6 A Phase II Trial Evaluating Irinotecan and Capecitabine in Patients With Relapsed/Refractory Upper Gastrointestinal Tumours Completed NCT00220168 Phase 4 Irinotecan, Capecitabine
7 A Prospective Randomized Trial of Transversus Abdominis Plane (TAP) INtraoperative Block With Bupivacaine/Dexamethasone aGainst Liposomal Bupivacaine (Exparel®): the TINGLE Trial Completed NCT03723447 Phase 4 Liposomal bupivacaine;Bupivacaine/epinephrine/dexamethasone
8 Assessment the Effect of Medium-Calorie TPN on Patients With Gastrointestinal Cancer Undergoing Surgery Completed NCT01700062 Phase 4
9 The Impact of Preoperative Oral Glutamine Intake on the Immunocompetence and Outcomes of Malnourished Patients Undergoing Major Abdominal Surgery Due to Malignancies - A Randomized, Placebo-controlled Pilot Study Completed NCT01552291 Phase 4 Placebo
10 Muscle Relaxation During Open Upper Abdominal Surgery - Can the Surgical Conditions be Optimized? Completed NCT02140593 Phase 4 Group STANDARD: Rocuronium 0.6 mg/kg followed by bolus rocuronium according to standard treatment combined with saline infusion (placebo).;Group DEEP: Rocuronium 0.6 mg/kg followed by rocuronium infusion with target level PTC 0-1 combined with bolus saline (placebo) mimicking standard treatment.
11 Glargine Insulin Versus Continous Regular Insulin in Diabetic Surgical Patients Receiving Parenteral Nutrition (GLUCOSE-in-PN) Completed NCT02216799 Phase 4 Glargine Insulin;Regular insulin
12 Comparison of Thromboembolic Events in Patients Undergoing Gastrointestinal Cancer Surgery and Thromboprophylactic Treatment With Two Enoxaparin Formulations (ENOXA® vs Lovenox®) Recruiting NCT02444572 Phase 4 Enoxaparin 4000 IU
13 Efficacy of Rapamycin (Sirolimus) in the Treatment of Blue Rubber Bleb Nevus Syndrome, Hereditary or Sporadic Venous Malformation Recruiting NCT03767660 Phase 4 Rapamycin
14 Clinical Trial on Ganoderma Spore Lipids Combined With Chemo in Patients With G.I. Cancers Unknown status NCT02785523 Phase 3 Ganoderma Spore Lipids;Placebo;Chemotherapy
15 Endoscopic Ultrasonography Guided Fine Needle Biopsy (EUS-FNB) vs. Single-incision Needle-knife (SINK) Biopsy for Diagnosis of Upper Gastrointestinal Subepithelial Lesions Unknown status NCT02866045 Phase 3
16 A Multinational, Randomized, Phase III Study of FOLFIRI With/Without Bevacizumab Versus Irinotecan With/Without Bevacizumab As Second-line Therapy in Patients With Metastatic Colorectal Cancer Unknown status NCT03303495 Phase 3 CPT-11;5-FU Bolus;5-FU Infusion;l-LV (dl-LV)
17 Surefire Infusion System vs. Standard Microcatheter Use During Holmium-166 Radioembolization for the Treatment of Colorectal Liver Metastases (SIM Trial) Unknown status NCT02208804 Phase 2, Phase 3
18 Sun Yat-sen University Cancer Center Completed NCT03674294 Phase 3 Aprepitant;Palonosetron;Dexamethasone;Placebo Oral Tablet
19 A Prospective Random Assignment Trial to Study Operative Debulking and Systemic Chemotherapy With or Without Intra-and Peri-Operative Intraperitoneal Chemotherapy for Subjects With Peritoneal Carcinomatosis From Low Grade Gastrointestinal Adenocarcinoma Completed NCT00052962 Phase 3
20 Monosialotetrahexosylganglioside Sodium Injection for Treatment of Oxaliplatin Induced Neurotoxicity in Gastrointestinal Cancer Completed NCT02486198 Phase 3 placebo;GM;oxaliplatin-based chemotherapy
21 A Randomized, Multicenter, Open-label, Phase III Study of Lapatinib (GW572016) in Combination With Weekly Paclitaxel Versus Weekly Paclitaxel Alone in the Second Line Treatment of ErbB2 Amplified Advanced Gastric Cancer Completed NCT00486954 Phase 3 Lapatinib;Paclitaxel
22 A Multinational, Randomized, Phase III Study of XELIRI With/Without Bevacizumab Versus FOLFIRI With/Without Bevacizumab As Second-line Therapy in Patients With Metastatic Colorectal Cancer Completed NCT01996306 Phase 3 CPT-11 (Irinotecan);5-FU Bolus;5-FU Infusion;l-LV (dl-LV);CPT-11 (Irinotecan);Capecitabine
23 Immunonutrition to Improve Quality of Life of Upper Gastrointestinal Cancer Patients Undergoing Oncological Treatment Completed NCT01423799 Phase 3
24 Home Enteral Nutrition in Malnourished Patients With Gastrointestinal Cancer: A Multicenter Randomized Clinical Trial Completed NCT02664974 Phase 3
25 Prospective Study on the Value of Subcutaneous Drains in Gastrointestinal Surgery Completed NCT00826410 Phase 3
26 A Randomized Clinical Trial of Melatonin Versus Placebo and the Effect on Appetite in Advanced Cancer Patients Completed NCT00513357 Phase 3 Melatonin;Placebo
27 A Randomized, Double-blind, Placebo-controlled, Phase III Study of Neoadjuvant-Adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Patients With Resectable Gastric and Gastroesophageal Junction Cancer (GC/GEJC) Recruiting NCT04592913 Phase 3 Durvalumab;FLOT chemotherapy
28 Perioperative Chemotherapy With FOLFIRINOX Regimen or FLOT Regimen for Resectable Gastric or Esophagogastric Junction Adenocarcinoma (Type II-III): Open-label Randomized Phase 2/3 Trial Recruiting NCT04393584 Phase 2, Phase 3 Irinotecan;5-FU;Leucovorin;Oxaliplatin;Docetaxel
29 Impact of Early Palliative Care on Overall Survival of Patients With Metastatic Upper Gastrointestinal Cancers, Treated With First-line Chemotherapy: a Randomized Phase III Trial Recruiting NCT02853474 Phase 3
30 A Phase 3, Multicenter, Open-label, Randomized Study of Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma Active, not recruiting NCT01964430 Phase 3 nab-Paclitaxel;Gemcitabine
31 A Phase III Study for ErbB2 Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Junction Adenocarcinoma Treated With Capecitabine Plus Oxaliplatin With or Without Lapatinib Active, not recruiting NCT00680901 Phase 3 Lapatinib;Placebo;Capecitabine;Oxaliplatin
32 A Phase III Study of Comparing the Maintenance Treatment of Apatinib, Capecitabine and Observation After First-line Therapy in Advanced Gastric Cancer Not yet recruiting NCT03889626 Phase 3 Apatinib;Capecitabine
33 A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients With Gastric or Rectal Cancers Undergoing Preoperative Chemoradiation Followed by Surgery Terminated NCT00254436 Phase 3 Procrit (epoetin alfa)
34 A Prospective, Randomised, Multicenter Phase II/III Clinical Trial to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT Versus Placebo Terminated NCT00332280 Phase 2, Phase 3 AMT2003
35 A Pilot Study of FOLFOX in Combination With Bevacizumab in Patients With Advanced Neuroendocrine Tumors Terminated NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
36 An Open-label, Randomized Phase 3 Study of the Efficacy and Tolerability of Linifanib (ABT-869) Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) Terminated NCT01009593 Phase 3 ABT-869;Sorafenib
37 Effect of 3 Day Pre-operative Immunonutrition Regimen on Clinical Outcome in Well-nourished Patients With Gastrointestinal Cancer Undergoing Surgery , a Randomised Double-blind Controlled Trial Terminated NCT01023412 Phase 3
38 A Randomized, Double Blind, Two Period, Placebo-Controlled Crossover Trial of a Sustained Release Methylphenidate in the Treatment of Fatigue in Cancer Patients Terminated NCT00516269 Phase 3 Methylphenidate;Placebo
39 Does Radiation Therapy Adversely Affect the Immune System, and Can Acupuncture Ameliorate the Effect? A Pilot Study Withdrawn NCT01422928 Phase 3
40 Safety Study of Combining Ultrasound Microbubbles and Chemotherapy to Treat Malignant Neoplasms of Liver Metastases From Gastrointestinal Tumors and Pancreatic Carcinoma Unknown status NCT02233205 Phase 1, Phase 2 platinum and gemcitabine
41 Celiac Plexus Radiosurgery for Pain Management in Advanced Cancer Patients - a Phase II Trial Unknown status NCT02356406 Phase 2
42 Is Greater Downstaging and Tumour Regression Observed When Surgery is Delayed to 12 Weeks After Completion of Chemoradiotherapy vs 6 Weeks? Unknown status NCT01037049 Phase 2
43 Phase 2 Study of DC-CIK Cells Combined With TACE in the Treatment of Hepatocellular Carcinoma Unknown status NCT02487017 Phase 2
44 Phase I/II Study With the Combination of Afatinib and Selumetinib in Advanced KRAS Mutant Positive and PIK3CA Wildtype Non-small Cell Lung Cancer Unknown status NCT02450656 Phase 1, Phase 2 Afatinib;Selumetinib;Docetaxel
45 Phase II Clinical Study of Patients Randomized, Open, Controlled Evaluation of Autologous Tumor Tissue Antigen Sensitized DC-CIK Cells Combined With Chemotherapy in the Treatment of Patients With Esophageal Resection Unknown status NCT02644863 Phase 2 Paclitaxel;Cisplatin
46 Randomized,Controlled,Multicenter Study of Autologous Tumor Lysate-pulsed Dendritic and Cytokine-induced Killer Cells(Ag-D-CIK) Combined With Chemotherapy for Gastric Cancer. Unknown status NCT02215837 Phase 2 Chemotherapy
47 Phase 2 Study of Autologous Tumor Lysate-pulsed DC-CIK Cell in Colorectal Cancer After Surgery Unknown status NCT02202928 Phase 2 Chemotherapy
48 Phase II Trail of Sorafenib Combined With Transarterial Chemoembolization in HBV-infected Patients With Intermediate Hepatocellular Carcinoma Unknown status NCT01556815 Phase 2
49 Study of Dihydropyrimidine Dehydrogenase for Predicting Efficacy and Safety to S-1 Plus Oxaliplatin in Gastrointestinal Cancer Unknown status NCT01608646 Phase 2 S-1 plus oxaliplatin
50 GCC 0319: Low Dose Upper Abdominal Radiation Therapy (LD-UART) + Gemcitabine in Patients With Advanced, Unresectable Pancreatic Cancer (PC) Completed NCT00390182 Phase 1, Phase 2 Gemcitabine

Search NIH Clinical Center for Gastrointestinal Carcinoma

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Imatinib mesylate

Genetic Tests for Gastrointestinal Carcinoma

Anatomical Context for Gastrointestinal Carcinoma

MalaCards organs/tissues related to Gastrointestinal Carcinoma:

40
Liver, Pancreas, Lymph Node, Colon, T Cells, Bone Marrow, Bone

Publications for Gastrointestinal Carcinoma

Articles related to Gastrointestinal Carcinoma:

(show top 50) (show all 874)
# Title Authors PMID Year
1
[Correlation of expression of P-glycoprotein and inhibitor of apoptosis proteins to chemosensitivity in gastrointestinal carcinoma tissues]. 54 61
19000447 2008
2
DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: results from genotyping study on 75 gastric carcinoma and colon carcinoma patients. 54 61
17848752 2007
3
Serum antibodies to EpCAM in healthy donors but not ulcerative colitis patients. 61 54
16034560 2006
4
Relationship between immunohistochemical evaluation of thymidylate synthase and proliferating cell nuclear antigen labeling index in gastrointestinal carcinoma. 54 61
15547732 2004
5
[CK20 mRNA expression in peripheral blood of patients with gastrointestinal carcinoma and its clinical significance]. 61 54
15522189 2004
6
Molecular detection of disseminated tumor cells in the peripheral blood in patients with gastrointestinal cancer. 54 61
12684893 2003
7
Gastrointestinal metastasis to the breast. 54 61
12464875 2002
8
Immunohistochemical detection of carcinoembryonic antigen in esophageal carcinomas: a comparison with other gastrointestinal neoplasms. 61 54
12168881 2002
9
Determination of disulfide bond assignments and N-glycosylation sites of the human gastrointestinal carcinoma antigen GA733-2 (CO17-1A, EGP, KS1-4, KSA, and Ep-CAM). 61 54
11080501 2001
10
Functional expression of CD11a on CD8+ cells is suppressed in regional lymph nodes with cancer involvement in patients with gastrointestinal carcinoma. 54 61
8859180 1996
11
Clinical evaluation of M43: a novel cancer-associated mucin epitope. 61 54
7684947 1993
12
Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells. 54 61
1569446 1992
13
Diagnostic utility of endoscopic brush cytology in upper gastrointestinal malignancies. 61
33275329 2021
14
Prevalence and endoscopic treatment outcomes of upper gastrointestinal neoplasms in familial adenomatous polyposis. 61
33709227 2021
15
Trends and Clinical Impact of Gastrointestinal Endoscopic Procedures on Acute Heart Failure in Spain (2002-2017). 61
33540753 2021
16
Comment on article by Christina Puhr Hannah et al.: Clinical characteristics and comparison of the outcome in young versus older patients with upper gastrointestinal carcinoma. 61
33638705 2021
17
Clinical characteristics and comparison of the outcome in young versus older patients with upper gastrointestinal carcinoma. 61
33638706 2021
18
Efficacy and safety of Seprafilm for preventing intestinal obstruction after gastrointestinal neoplasms surgery: a systematic review and meta-analysis. 61
33459577 2021
19
Endoscopic Submucosal Dissection in North America: A Large Prospective Multicenter Study. 61
33610532 2021
20
Effects of colorectal endoscopic submucosal dissection on postoperative abdominal symptoms: a prospective observational study. 61
33502617 2021
21
Recent Research on Gastrointestinal Carcinoma. 61
33477500 2021
22
Evaluation and Comparison of Predictive Value of Tumor Regression Grades according to Mandard and Becker in Locally Advanced Gastric Adenocarcinoma. 61
32777876 2021
23
Gastrointestinal Stromal Tumors (GISTs): Novel Therapeutic Strategies with Immunotherapy and Small Molecules. 61
33419029 2021
24
Undifferentiated large cell/rhabdoid carcinoma presenting in the intestines of patients with concurrent or recent non-small cell lung cancer (NSCLC): clinicopathologic and molecular analysis of 14 cases indicates an unusual pattern of dedifferentiated metastases. 61
33506327 2021
25
Clinical characteristics and comparison of the outcome in young versus older patients with upper gastrointestinal carcinoma. 61
32617700 2020
26
Digestive tract neoplasms in young individuals: Demographics, staging and risk factors. 61
33295088 2020
27
Football Size Jejunal Gastrointestinal Stromal Tumour. 61
33415061 2020
28
Uterine Cervical Neoplasm Diagnosed by Flexible Magnifying Endoscopy with Narrow Band Imaging. 61
33158128 2020
29
The microbiome, genetics, and gastrointestinal neoplasms: the evolving field of molecular pathological epidemiology to analyze the tumor-immune-microbiome interaction. 61
33180176 2020
30
Effect of anticoagulants on the risk of delayed bleeding after colorectal endoscopic submucosal dissection. 61
33140021 2020
31
Ex vivo porcine model study on the treatment outcomes of scissor-type knife versus needle-type knife in endoscopic submucosal dissection performed by trainees. 61
33213449 2020
32
Clinical benefit of the multibending endoscope for gastric endoscopic submucosal dissection: a randomized controlled trial. 61
33152774 2020
33
Exploration of the characteristics of chronotypes in upper gastrointestinal tract diseases: a multicenter study in Japan. 61
33059467 2020
34
Current prognostic and predictive biomarkers for gastrointestinal tumors in clinical practice. 61
33179625 2020
35
New advances in radiomics of gastrointestinal stromal tumors. 61
32921953 2020
36
Histological clues to the diagnosis of metastasis to the breast from extramammary malignancies. 61
32396659 2020
37
Small Bowel Gastrointestinal Stromal Tumor as a Gateway for Streptococcus anginosus Causing Multiple Liver Abscesses. 61
32494319 2020
38
Methods that Assist Traction during Endoscopic Submucosal Dissection of Superficial Gastrointestinal Cancers: A Systematic Literature Review. 61
31914722 2020
39
Goblet Cell Adenocarcinoma With Heterotopic Ossification: A Rare Case Report and Review of Literature. 61
32607295 2020
40
Endoscopic full-thickness resection of early colorectal neoplasms using an endoscopic submucosal dissection knife: a retrospective multicenter study. 61
32355878 2020
41
The effect of scissor-type versus non-scissor-type knives on the technical outcomes in endoscopic submucosal dissection for superficial esophageal cancer: a multi-center retrospective study. 61
31617891 2020
42
The Relationship between KIT Copy Number Variation, Protein Expression, and Angiogenesis in Sporadic Breast Cancer. 61
32821750 2020
43
Learning Curve for Endoscopic Submucosal Dissection With an Untutored, Prevalence-Based Approach in the United States. 61
31220645 2020
44
Hemorrhage control during gastric endoscopic submucosal dissection: Techniques using uncovered knives. 61
32055690 2020
45
Cathepsin S as a target in gastric cancer. 61
31929878 2020
46
Gastrointestinal stromal tumours and other primary gastrointestinal neoplasms. A single-center experience. 61
33554950 2020
47
Spontaneous perforation of jejunal gastrointestinal stromal tumor: A case report. 61
32629218 2020
48
Voluminous abdominal gastrointestinal stromal tumor of unknown origin manifested with bleeding in a young man: synchronous management of the emergency and oncological approach-case report. 61
33179005 2020
49
Diagnostic, clinicopathologic, therapeutic and prognostic value of Plasma Heat Shock Protein 90 levels in patients with advanced Gastrointestinal Carcinoma. 61
32922531 2020
50
Tumor Regression Grade Predicts Survival in Locally Advanced Gastric Adenocarcinoma Patients with Lymph Node Metastasis. 61
32733550 2020

Variations for Gastrointestinal Carcinoma

ClinVar genetic disease variations for Gastrointestinal Carcinoma:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 ELN NM_000501.4(ELN):c.898A>T (p.Thr300Ser) SNV Uncertain significance 523433 rs766735416 GRCh37: 7:73466262-73466262
GRCh38: 7:74051932-74051932
2 CHEK2 NM_007194.4(CHEK2):c.470T>C (p.Ile157Thr) SNV Uncertain significance 5591 rs17879961 GRCh37: 22:29121087-29121087
GRCh38: 22:28725099-28725099

Copy number variations for Gastrointestinal Carcinoma from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 19435 1 150300000 155000000 Amplification Gastrointestinal cancer
2 119187 18 1 2900000 LOH TYMS Gastrointestinal cancer
3 119685 18 16100000 23300000 Deletion HRH4 Gastrointestinal cancer

Expression for Gastrointestinal Carcinoma

Search GEO for disease gene expression data for Gastrointestinal Carcinoma.

Pathways for Gastrointestinal Carcinoma

GO Terms for Gastrointestinal Carcinoma

Cellular components related to Gastrointestinal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Golgi cisterna membrane GO:0032580 9.13 ST3GAL3 FUT6 FUT5
2 apical plasma membrane GO:0016324 9.1 MUC1 EPCAM CEACAM7 CEACAM6 CEACAM5 CD44

Biological processes related to Gastrointestinal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.88 TP53 IL6 EPCAM CEACAM5 CD44
2 leukocyte migration GO:0050900 9.56 EPCAM CEACAM6 CEACAM5 CD44
3 fucosylation GO:0036065 9.46 FUT6 FUT5
4 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.43 TP53 IL6
5 positive regulation of stem cell proliferation GO:2000648 9.4 PTPRC EPCAM
6 bone marrow development GO:0048539 9.37 TP53 PTPRC
7 L-fucose catabolic process GO:0042355 9.32 FUT6 FUT5
8 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.16 TP53 MUC1
9 regulation of somitogenesis GO:0014807 8.96 CDX2 CDX1
10 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 8.92 TP53 PTPRC IL6 CD44

Molecular functions related to Gastrointestinal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 fucosyltransferase activity GO:0008417 9.16 FUT6 FUT5
2 alpha-(1->3)-fucosyltransferase activity GO:0046920 8.96 FUT6 FUT5
3 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase activity GO:0017083 8.62 FUT6 FUT5

Sources for Gastrointestinal Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....